Health Business

TAKE Solutions announces Preferential Allotment of INR 250 crores

Sustains growth momentum with Q3 FY18 profits of INR 411 Mn; Revenue saw a growth of 18.9% in INR Y-o-Y

Figures in INR million unless mentioned Q3 FY18 Q3 FY17 Y-o-Y change (%)
Revenue 4,080 3,431 18.9%
EBITDA 798 693 15.2%
PATMI 411 370 11.0%
Diluted EPS 3.13 2.81 11.4%

TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a globally recognized domain intensive services provider in Life Sciences, today announced its financial results for Q3 FY18. The Company carried forward the momentum witnessed in Q2 FY18, reporting strong Q3 revenue and profit figures of INR 4,080 Mn and INR 411 Mn.

take

Srinivasan H R, Vice Chairman and Managing DirectorTAKE Solutions said, “This quarter has witnessed strong business growth as can be seen in the financial results. In response to the emerging growth possibilities we are delighted to announce a preferential allotment of INR 250 crores to the promoters. The funds raised through this preferential issue will be used to capitalize on our opportunities and scale our business in the Clinical and Regulatory spaces inorganically through strategic acquisitions in North America and Europe markets.”

Highlights of the quarter:

–      EBITDA grew 15.2% in INR Y-o-Y

–      Revenue saw a growth 18.9% in INR Y-o-Y.

–      Life Sciences revenue grew by 25.4 % (INR) Y-o-Y.

–      Customer base of small and medium pharma for PharmaReady software has crossed 150 and climbing steadily

–      Scales BA/BE business with an 80 bedded Clinical Pharmacology Unit which will be ready to commence operations soon

–      Aligns all capabilities to digitize research and development of life sciences

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top